Cover Image
Market Research Report

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

Published by GlobalData Product code 489881
Published Content info 797 Pages
Delivery time: 1-2 business days
Price
Back to Top
Neurodegenerative Disorders Drug Development Pipeline Review, 2017
Published: March 21, 2017 Content info: 797 Pages
Description

Executive Summary

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

The report provides comprehensive information on the pipeline development landscape for is Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

  • Which companies are the most active within the pipeline for neurodegenerative disorders?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
Product Code: GBIHC006IDB

Table of Contents

GBI Research Report Guidance

Executive Summary

Table of Contents

  • List of Tables
  • List of Figures

Introduction

  • Neurodegenerative Disorders Report Coverage
  • Alzheimer's Disease Overview
  • Amyotrophic Lateral Sclerosis Overview
  • Huntington Disease Overview
  • Multiple Sclerosis Overview
  • Parkinson's Disease Overview

Therapeutics Development

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Therapeutics under Development by Companies

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Therapeutics under Investigation by Universities/Institutes

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Pipeline Products Glance

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Products under Development by Companies

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Products under Investigation by Universities/Institutes

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Companies Involved in Therapeutics Development

  • Alzheimer's Disease

Amyotrophic Lateral Sclerosis

  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Therapeutics Assessment
  • Alzheimer's Disease

Amyotrophic Lateral Sclerosis

  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Dormant Projects
  • Alzheimer's Disease

Amyotrophic Lateral Sclerosis

  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Discontinued Products
  • Alzheimer's Disease

Amyotrophic Lateral Sclerosis

  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Product Development Milestones

  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Multiple Sclerosis
  • Parkinson's Disease

Appendix

  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Alzheimer's Disease
  • Number of Products under Development for Alzheimer's Disease - Comparative Analysis
  • Number of Products under Development for Amyotrophic Lateral Sclerosis
  • Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis
  • Number of Products under Development for Huntington Disease
  • Number of Products under Development for Huntington Disease - Comparative Analysis
  • Number of Products under Development for Multiple Sclerosis
  • Number of Products under Development for Multiple Sclerosis - Comparative Analysis
  • Number of Products under Development for Parkinson's Disease
  • Number of Products under Development for Parkinson's Disease - Comparative Analysis
  • Number of Products under Development by Companies, Alzheimer's Disease
  • Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis
  • Number of Products under Development by Companies, Huntington Disease
  • Number of Products under Development by Companies, Multiple Sclerosis
  • Number of Products under Development by Companies, Parkinson's Disease
  • Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease
  • Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis
  • Number of Products under Investigation by Universities/Institutes, Huntington Disease
  • Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis
  • Number of Products under Investigation by Universities/Institutes, Parkinson's Disease
  • Comparative Analysis by Late Stage Development, Alzheimer's Disease
  • Comparative Analysis by Clinical Stage Development, Alzheimer's Disease
  • Comparative Analysis by Early Stage Development, Alzheimer's Disease
  • Comparative Analysis by Unknown Stage Development, Alzheimer's Disease
  • Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis
  • Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis
  • Comparative Analysis by Early Stage Development, Amyotrophic Lateral Sclerosis
  • Comparative Analysis by Unknown Stage Development, Amyotrophic Lateral Sclerosis
  • Comparative Analysis by Late Stage Development, Huntington Disease
  • Comparative Analysis by Clinical Stage Development, Huntington Disease
  • Comparative Analysis by Early Stage Development, Huntington Disease
  • Comparative Analysis by Late Stage Development, Multiple Sclerosis
  • Comparative Analysis by Clinical Stage Development, Multiple Sclerosis
  • Comparative Analysis by Early Stage Development, Multiple Sclerosis
  • Comparative Analysis by Unknown Stage Development, Multiple Sclerosis
  • Comparative Analysis by Late Stage Development, Parkinson's Disease
  • Comparative Analysis by Clinical Stage Development, Parkinson's Disease
  • Comparative Analysis by Early Stage Development, Parkinson's Disease
  • Comparative Analysis by Unknown Stage Development, Parkinson's Disease
  • Products under Development by Companies, Alzheimer's Disease
  • Products under Development by Companies, Amyotrophic Lateral Sclerosis
  • Products under Development by Companies, Huntington Disease
  • Products under Development by Companies, Multiple Sclerosis
  • Products under Development by Companies, Parkinson's Disease
  • Products under Investigation by Universities/Institutes, Alzheimer's Disease
  • Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis
  • Products under Investigation by Universities/Institutes, Huntington Disease
  • Products under Investigation by Universities/Institutes, Multiple Sclerosis
  • Products under Investigation by Universities/Institutes, Parkinson's Disease
  • Alzheimer's Disease - Pipeline by AB Science SA,
  • Alzheimer's Disease - Pipeline by AbbVie Inc,
  • Alzheimer's Disease - Pipeline by AC Immune SA,
  • Alzheimer's Disease - Pipeline by Accera, Inc.,
  • Alzheimer's Disease - Pipeline by Acelot, Inc.,
  • Alzheimer's Disease - Pipeline by Actinogen Limited,
  • Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals, Inc.,
  • Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd,
  • Alzheimer's Disease - Pipeline by Affibody AB,
  • Alzheimer's Disease - Pipeline by AFFiRiS AG,
  • Alzheimer's Disease - Pipeline by Alector LLC,
  • Alzheimer's Disease - Pipeline by Alkermes Plc,
  • Alzheimer's Disease - Pipeline by Allergan Plc,
  • Alzheimer's Disease - Pipeline by Allinky Biopharma,
  • Alzheimer's Disease - Pipeline by ALSP, Inc.,
  • Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd,
  • Alzheimer's Disease - Pipeline by Alzinova AB,
  • Alzheimer's Disease - Pipeline by AlzProtect SAS,
  • Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc.,
  • Alzheimer's Disease - Pipeline by Amgen Inc.,
  • Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp.,
  • Alzheimer's Disease - Pipeline by Aphios Corporation,
  • Alzheimer's Disease - Pipeline by Apodemus AB,
  • Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences, S.L.,
  • Alzheimer's Disease - Pipeline by Araclon Biotech, S.L.,
  • Alzheimer's Disease - Pipeline by Archer Pharmaceuticals, Inc.,
  • Alzheimer's Disease - Pipeline by ArmaGen Inc.,
  • Alzheimer's Disease - Pipeline by Artery Therapeutics, Inc.,
  • Alzheimer's Disease - Pipeline by AskAt Inc.,
  • Alzheimer's Disease - Pipeline by Astellas Pharma Inc.,
  • Alzheimer's Disease - Pipeline by AstraZeneca Plc,
  • Alzheimer's Disease - Pipeline by Asubio Pharma Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Ausio Pharmaceuticals, LLC,
  • Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc.,
  • Alzheimer's Disease - Pipeline by Axon Neuroscience SE,
  • Alzheimer's Disease - Pipeline by Axovant Sciences Ltd.,
  • Alzheimer's Disease - Pipeline by Axsome Therapeutics, Inc.,
  • Alzheimer's Disease - Pipeline by Axxam SpA,
  • Alzheimer's Disease - Pipeline by Beactica AB,
  • Alzheimer's Disease - Pipeline by Berg LLC,
  • Alzheimer's Disease - Pipeline by BioArctic Neuroscience AB,
  • Alzheimer's Disease - Pipeline by Bioasis Technologies Inc.,
  • Alzheimer's Disease - Pipeline by Biogen Inc,
  • Alzheimer's Disease - Pipeline by Biomar Microbial Technologies,
  • Alzheimer's Disease - Pipeline by Bionature E.A. Ltd.,
  • Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH,
  • Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company,
  • Alzheimer's Disease - Pipeline by Bsim2,
  • Alzheimer's Disease - Pipeline by Cardax Pharmaceuticals, Inc.,
  • Alzheimer's Disease - Pipeline by Carna Biosciences, Inc.,
  • Alzheimer's Disease - Pipeline by Celon Pharma Sp. z o.o.,
  • Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation,
  • Alzheimer's Disease - Pipeline by Clera Inc.,
  • Alzheimer's Disease - Pipeline by Cognition Therapeutics, Inc.,
  • Alzheimer's Disease - Pipeline by Cognosci, Inc.,
  • Alzheimer's Disease - Pipeline by CohBar, Inc.,
  • Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt. Ltd.,
  • Alzheimer's Disease - Pipeline by ContraVir Pharmaceuticals, Inc.,
  • Alzheimer's Disease - Pipeline by Corium International, Inc.,
  • Alzheimer's Disease - Pipeline by Coronis Partners Ltd.,
  • Alzheimer's Disease - Pipeline by Cortice Biosciences, Inc.,
  • Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc.,
  • Alzheimer's Disease - Pipeline by Crossbeta Biosciences B.V.,
  • Alzheimer's Disease - Pipeline by D-Pharm Ltd.,
  • Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Daiichi Sankyo Company, Limited,
  • Alzheimer's Disease - Pipeline by Daval International Limited,
  • Alzheimer's Disease - Pipeline by DermaXon, LLC,
  • Alzheimer's Disease - Pipeline by Dongkook Pharmaceutical Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Eisai Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Eli Lilly and Company,
  • Alzheimer's Disease - Pipeline by Emergent BioSolutions Inc.,
  • Alzheimer's Disease - Pipeline by EncephRx, Inc.,
  • Alzheimer's Disease - Pipeline by Endece, LLC,
  • Alzheimer's Disease - Pipeline by ENKAM Pharmaceuticals A/S,
  • Alzheimer's Disease - Pipeline by Ensemble Therapeutics Corporation,
  • Alzheimer's Disease - Pipeline by Ensol Biosciences Inc.,
  • Alzheimer's Disease - Pipeline by Epigen Biosciences, Inc.,
  • Alzheimer's Disease - Pipeline by Euroscreen S.A.,
  • Alzheimer's Disease - Pipeline by Evotec AG,
  • Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd.,
  • Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc.,
  • Alzheimer's Disease - Pipeline by Genentech, Inc.,
  • Alzheimer's Disease - Pipeline by Genervon Biopharmaceuticals, LLC,
  • Alzheimer's Disease - Pipeline by GlaxoSmithKline Plc,
  • Alzheimer's Disease - Pipeline by GliaCure Inc.,
  • Alzheimer's Disease - Pipeline by Glialogix, Inc.,
  • Alzheimer's Disease - Pipeline by Golden Biotechnology Corp.,
  • Alzheimer's Disease - Pipeline by Grifols, S.A.,
  • Alzheimer's Disease - Pipeline by H. Lundbeck A/S,
  • Alzheimer's Disease - Pipeline by Heptares Therapeutics Limited,
  • Alzheimer's Disease - Pipeline by HitGen LTD,
  • Alzheimer's Disease - Pipeline by Humanetics Corporation,
  • Alzheimer's Disease - Pipeline by Ichor Medical Systems, Inc.,
  • Alzheimer's Disease - Pipeline by Icure Pharmaceutical Inc.,
  • Alzheimer's Disease - Pipeline by Immungenetics AG,
  • Alzheimer's Disease - Pipeline by Impel NeuroPharma, Inc.,
  • Alzheimer's Disease - Pipeline by ImStar Therapeutics Inc.,
  • Alzheimer's Disease - Pipeline by Inovio Pharmaceuticals, Inc.,
  • Alzheimer's Disease - Pipeline by IntelGenx Corp.,
  • Alzheimer's Disease - Pipeline by Intellect Neurosciences, Inc.,
  • Alzheimer's Disease - Pipeline by Intra-Cellular Therapies, Inc.,
  • Alzheimer's Disease - Pipeline by INVENT Pharmaceuticals, Inc.,
  • Alzheimer's Disease - Pipeline by Io Therapeutics, Inc.,
  • Alzheimer's Disease - Pipeline by Iproteos S.L.,
  • Alzheimer's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Johnson & Johnson,
  • Alzheimer's Disease - Pipeline by K-Stemcell Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Kadmon Corporation, LLC,
  • Alzheimer's Disease - Pipeline by Kalgene Pharmaceuticals Inc.,
  • Alzheimer's Disease - Pipeline by Kareus Therapeutics, SA,
  • Alzheimer's Disease - Pipeline by KineMed, Inc.,
  • Alzheimer's Disease - Pipeline by Krenitsky Pharmaceuticals Inc.,
  • Alzheimer's Disease - Pipeline by Kyowa Hakko Kirin Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Lead Discovery Center GmbH,
  • Alzheimer's Disease - Pipeline by Les Laboratoires Servier SAS,
  • Alzheimer's Disease - Pipeline by Lipopharma Therapeutics SL,
  • Alzheimer's Disease - Pipeline by Living Cell Technologies Limited,
  • Alzheimer's Disease - Pipeline by Lupin Limited,
  • Alzheimer's Disease - Pipeline by M3 Biotechnology, Inc.,
  • Alzheimer's Disease - Pipeline by ManRos Therapeutics,
  • Alzheimer's Disease - Pipeline by MedDay SA,
  • Alzheimer's Disease - Pipeline by Medestea Research & Production S.p.A.,
  • Alzheimer's Disease - Pipeline by MedImmune, LLC,
  • Alzheimer's Disease - Pipeline by Medisyn Technologies, Inc.,
  • Alzheimer's Disease - Pipeline by MEDRx Co., Ltd.,
  • Alzheimer's Disease - Pipeline by Merck & Co., Inc.,
  • Alzheimer's Disease - Pipeline by Metabolic Solutions Development Company, LLC,

List of Figures

  • Number of Products under Development for Alzheimer's Disease
  • Number of Products under Development for Alzheimer's Disease - Comparative Analysis
  • Number of Products under Development for Amyotrophic Lateral Sclerosis
  • Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis
  • Number of Products under Development for Huntington Disease
  • Number of Products under Development for Huntington Disease - Comparative Analysis
  • Number of Products under Development for Multiple Sclerosis
  • Number of Products under Development for Multiple Sclerosis - Comparative Analysis
  • Number of Products under Development for Parkinson's Disease
  • Number of Products under Development for Parkinson's Disease - Comparative Analysis
  • Number of Products under Development by Companies, Alzheimer's Disease
  • Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis
  • Number of Products under Development by Companies, Huntington Disease
  • Number of Products under Development by Companies, Multiple Sclerosis
  • Number of Products under Development by Companies, Parkinson's Disease
  • Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease
  • Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis
  • Number of Products under Investigation by Universities/Institutes, Huntington Disease
  • Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis
  • Number of Products under Investigation by Universities/Institutes, Parkinson's Disease
  • Comparative Analysis by Late Stage Development, Alzheimer's Disease
  • Comparative Analysis by Clinical Stage Development, Alzheimer's Disease
  • Comparative Analysis by Early Stage Products, Alzheimer's Disease
  • Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis
  • Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis
  • Comparative Analysis by Early Stage Products, Amyotrophic Lateral Sclerosis
  • Comparative Analysis by Late Stage Development, Huntington Disease
  • Comparative Analysis by Clinical Stage Development, Huntington Disease
  • Comparative Analysis by Early Stage Products, Huntington Disease
  • Comparative Analysis by Late Stage Development, Multiple Sclerosis
  • Comparative Analysis by Clinical Stage Development, Multiple Sclerosis
  • Comparative Analysis by Early Stage Products, Multiple Sclerosis
  • Comparative Analysis by Late Stage Development, Parkinson's Disease
  • Comparative Analysis by Clinical Stage Development, Parkinson's Disease
  • Comparative Analysis by Early Stage Products, Parkinson's Disease
  • Comparative Analysis by Unknown Stage Development, Parkinson's Disease
  • Assessment by Monotherapy Products, Alzheimer's Disease
  • Assessment by Combination Products, Alzheimer's Disease
  • Number of Products by Top 10 Targets, Alzheimer's Disease
  • Number of Products by Stage and Top 10 Targets, Alzheimer's Disease
  • Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease
  • Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease
  • Number of Products by Top 10 Routes of Administration, Alzheimer's Disease
  • Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease
  • Number of Products by Top 10 Molecule Types, Alzheimer's Disease
  • Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease
  • Assessment by Monotherapy Products, Amyotrophic Lateral Sclerosis
  • Assessment by Combination Products, Amyotrophic Lateral Sclerosis
  • Number of Products by Top 10 Targets, Amyotrophic Lateral Sclerosis
  • Number of Products by Stage and Top 10 Targets, Amyotrophic Lateral Sclerosis
  • Number of Products by Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis
  • Number of Products by Stage and Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis
  • Number of Products by Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis
  • Number of Products by Stage and Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis
  • Number of Products by Top 10 Molecule Types, Amyotrophic Lateral Sclerosis
  • Number of Products by Stage and Top 10 Molecule Types, Amyotrophic Lateral Sclerosis
  • Assessment by Monotherapy Products, Huntington Disease
  • Number of Products by Top 10 Targets, Huntington Disease
  • Number of Products by Stage and Top 10 Targets, Huntington Disease
  • Number of Products by Top 10 Mechanism of Actions, Huntington Disease
  • Number of Products by Stage and Top 10 Mechanism of Actions, Huntington Disease
  • Number of Products by Top 10 Routes of Administration, Huntington Disease
  • Number of Products by Stage and Top 10 Routes of Administration, Huntington Disease
  • Number of Products by Top 10 Molecule Types, Huntington Disease
  • Number of Products by Stage and Top 10 Molecule Types, Huntington Disease
  • Assessment by Monotherapy Products, Multiple Sclerosis
  • Number of Products by Top 10 Targets, Multiple Sclerosis
  • Number of Products by Stage and Top 10 Targets, Multiple Sclerosis
  • Number of Products by Top 10 Mechanism of Actions, Multiple Sclerosis
  • Number of Products by Stage and Top 10 Mechanism of Actions, Multiple Sclerosis
  • Number of Products by Top 10 Routes of Administration, Multiple Sclerosis
  • Number of Products by Stage and Top 10 Routes of Administration, Multiple Sclerosis
  • Number of Products by Top 10 Molecule Types, Multiple Sclerosis
  • Number of Products by Stage and Top 10 Molecule Types, Multiple Sclerosis
  • Assessment by Monotherapy Products, Parkinson's Disease
  • Assessment by Combination Products, Parkinson's Disease
  • Number of Products by Top 10 Targets, Parkinson's Disease
  • Number of Products by Stage and Top 10 Targets, Parkinson's Disease
  • Number of Products by Top 10 Mechanism of Actions, Parkinson's Disease
  • Number of Products by Stage and Top 10 Mechanism of Actions, Parkinson's Disease
  • Number of Products by Top 10 Routes of Administration, Parkinson's Disease
  • Number of Products by Stage and Top 10 Routes of Administration, Parkinson's Disease
  • Number of Products by Top 10 Molecule Types, Parkinson's Disease
  • Number of Products by Stage and Top 10 Molecule Types, Parkinson's Disease
Back to Top